Linked Life Data

12763210

Source:http://linkedlifedata.com/resource/pubmed/id/12763210

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12763210rdf:typepubmed:Citationlld:pubmed
pubmed-article:12763210lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0043210lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0442045lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0027627lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0290883lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0935916lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0232970lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0206012lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C1548228lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C1515021lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C1518392lld:lifeskim
pubmed-article:12763210lifeskim:mentionsumls-concept:C0701491lld:lifeskim
pubmed-article:12763210pubmed:issue9lld:pubmed
pubmed-article:12763210pubmed:dateCreated2003-5-23lld:pubmed
pubmed-article:12763210pubmed:abstractTextThe efficacy of fulvestrant (Faslodex), a novel oestrogen receptor (ER) antagonist that downregulates the ER and has no known agonist effects, was compared with the aromatase inhibitor anastrozole (Arimidex) for the second-line treatment of advanced breast cancer in postmenopausal women with visceral and non-visceral metastases. Assessment was by means of a retrospective subgroup analysis of combined data from two randomised, phase III trials. Objective response (OR) rates were similar in patients treated with fulvestrant and anastrozole, respectively (21.9% versus 19.3%-patients with no visceral metastases; 15.7% versus 13.2%-all of the patients with visceral metastases; 18.8% versus 14.0%-patients with visceral metastases only). The proportion of patients with clinical benefit (CB) was also similar between treatments and between subgroups with and without visceral disease. Fulvestrant is at least as effective as anastrozole, providing a valuable treatment option for advanced breast cancer in postmenopausal women with visceral metastases who have failed on prior endocrine therapy.lld:pubmed
pubmed-article:12763210pubmed:languageenglld:pubmed
pubmed-article:12763210pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12763210pubmed:citationSubsetIMlld:pubmed
pubmed-article:12763210pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12763210pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12763210pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12763210pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12763210pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12763210pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12763210pubmed:statusMEDLINElld:pubmed
pubmed-article:12763210pubmed:monthJunlld:pubmed
pubmed-article:12763210pubmed:issn0959-8049lld:pubmed
pubmed-article:12763210pubmed:authorpubmed-author:OsborneC KCKlld:pubmed
pubmed-article:12763210pubmed:authorpubmed-author:MauriacLLlld:pubmed
pubmed-article:12763210pubmed:authorpubmed-author:GertlerS ZSZlld:pubmed
pubmed-article:12763210pubmed:authorpubmed-author:Quaresma...lld:pubmed
pubmed-article:12763210pubmed:authorpubmed-author:PippenJ EJElld:pubmed
pubmed-article:12763210pubmed:issnTypePrintlld:pubmed
pubmed-article:12763210pubmed:volume39lld:pubmed
pubmed-article:12763210pubmed:ownerNLMlld:pubmed
pubmed-article:12763210pubmed:authorsCompleteYlld:pubmed
pubmed-article:12763210pubmed:pagination1228-33lld:pubmed
pubmed-article:12763210pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:meshHeadingpubmed-meshheading:12763210...lld:pubmed
pubmed-article:12763210pubmed:year2003lld:pubmed
pubmed-article:12763210pubmed:articleTitleFulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.lld:pubmed
pubmed-article:12763210pubmed:affiliationInstitut Bergonié, Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, 229, cours de l'Argonne, 33076, Bordeaux, France. mauriac@bergonie.orglld:pubmed
pubmed-article:12763210pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12763210pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12763210pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12763210pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12763210pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:12763210pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:12763210pubmed:publicationTypeClinical Trial, Phase IIIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12763210lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12763210lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12763210lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12763210lld:pubmed